Fulgent Genetics to Announce Third Quarter 2020 Financial Results on Monday November 9, 2020
October 26 2020 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”) today announced that it will release its third quarter
2020 financial results after the market closes on Monday November
9, 2020. The company’s Chairman and Chief Executive Officer Ming
Hsieh, Chief Financial Officer Paul Kim and Chief Commercial
Officer Brandon Perthuis will host a conference call for the
investment community the same day at 4:30 PM ET (1:30 PM PT) to
discuss the results and answer questions.
The call can be accessed through a live audio webcast in the
Investors section of the company’s website,
http://ir.fulgentgenetics.com, and through a live conference call
by dialing (855) 321-9535 using the conference ID 1466548. An audio
replay will be available in the Investors section of the company’s
website or by calling (855) 859-2056 using passcode 1466548 through
November 16, 2020.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a
broad, flexible test menu and the ability to continually expand and
improve its proprietary genetic reference library while maintaining
accessible pricing, high accuracy and competitive turnaround times.
Combining next generation sequencing (“NGS”) with its technology
platform, the company performs full-gene sequencing with
deletion/duplication analysis in an array of panels that can be
tailored to meet specific customer needs. In 2019, the company
launched its first patient-initiated product, Picture Genetics, a
new line of at-home screening tests that combines the company’s
advanced NGS solutions with actionable results and genetic
counseling options for individuals. Since March 2020, the company
has commercially launched several tests for the detection of
SARS-CoV-2, the virus that causes the novel coronavirus
(“COVID-19”), including NGS and reverse transcription polymerase
chain reaction (“RT-PCR”) - based tests. The company has received
Emergency Use Authorization (“EUA”) from the U.S. Food and Drug
Administration (“FDA”) for the RT-PCR-based tests for the detection
of SARS-CoV-2 using upper respiratory specimens (nasal,
nasopharyngeal, and oropharyngeal swabs) and for the at-home
testing service through Picture Genetics. A cornerstone of the
company’s business is its ability to provide expansive options and
flexibility for all clients’ unique testing needs through a
comprehensive technology offering including cloud computing,
pipeline services, record management, web portal services, clinical
workflow, sequencing as a service and automated lab services.
Investor Relations
Contacts:The Blueshirt
GroupNicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Sep 2023 to Sep 2024